TP53 and Alzheimer disease: Notably, mitochondrially targeted p53 (mito-p53) could reduce mitochondrial DNA-encoded ND2 and ND4 gene expression, resulting in increased ROS levels, while SIRT3 overexpression restored the expression of ND2 and ND4 and improved mitochondrial oxygen consumption by repressing mito-p53 activity in patients with AD [80].